International Journal of Medical Science in Clinical Research and Review
Online ISSN: 2581-8945
Available Online at https://ijmscrr.in/ Volume 7|Issue 06 (November-December) |2024 Page: 1381-1392

Review Paper

The Role of Gut Microbiome in Mental Health: A Systematic Review and Meta-Analysis

Authors:
Dr. Syed Abid[1], Dr. Humaira Jannath[2], Dr. Farhana Chowdhury[3], Dr. Marzana Hossain Mohona[4], Dr. Mostofa Mohiuddin Al Faruque[5], Dr. Ahaana Awal[6]

[1]*East and North Hertfordshire NHS Trust*
[2]*East and North Hertfordshire NHS Trust*
[3]*University Hospitals Birmingham NHS Foundation Trust*
[4]*Portsmouth hospitals university NHS trust*
[5]*Sun General Hospital*
[6]*Sun General Hospital*

Corresponding Author:
Dr. Humaira Jannath, East and North Hertfordshire NHS Trust

Article Received: 22-October -2024, Revised: 12-November-2024, Accepted: 02-December-2024

ABSTRACT:
The gut-brain axis, a bidirectional communication pathway involving the gut microbiome, plays a critical role in mental health. This systematic review and meta-analysis examine the relationship between gut microbiome composition and mental health disorders such as depression and anxiety. A comprehensive analysis of 32 randomized controlled and observational studies, revealed significant associations between gut dysbiosis and mental health outcomes. Reduced microbial diversity and altered abundance of specific bacterial species such as increased Bacteroidetes and decreased Firmicutes, were linked to higher risks of depression and anxiety. Mechanistic pathways, including neurotransmitter modulation, vagal nerve signaling, and immune system interactions, were identified as potential mediators of this relationship. Microbiome-based interventions, such as probiotics and prebiotics, demonstrated promising effects in alleviating symptoms of mental health disorders. These findings highlight the potential of targeting the gut microbiome as an adjunctive therapy for mental health conditions and emphasize the need for further longitudinal and mechanistic studies to establish causality and optimize treatment strategies.
Categories: Psychiatry, Gastroenterology, Nutrition

Keywords: meta-analysis, systematic review, microbiome-based interventions, mental health disorders, gut-brain axis

INTRODUCTION:

The intricate relationship between the gut and the brain, often referred to as the gut-brain axis, has been a growing area of interest in recent years. This bidirectional communication pathway involves a complex interplay of neurotransmitters, hormones, and the immune system, all of which are influenced by the gut microbiome [1, 2]. Emerging evidence suggests a strong association between the composition of the gut microbiome and the development of mental health disorders, including depression, anxiety, and stress [3, 4].

The gut microbiome, a vast ecosystem of microorganisms residing in the gastrointestinal tract, plays a crucial role in various physiological functions, including digestion, nutrient absorption, and immune regulation [5, 6]. Alterations in the composition and diversity of the gut microbiome, often referred to as dysbiosis, have been linked to a variety of health conditions, including gastrointestinal disorders, autoimmune diseases, and metabolic disorders [7, 8]. Recent studies have highlighted the potential role of the gut microbiome in influencing mental health through several mechanisms. One proposed mechanism involves the production of neurotransmitters, such as serotonin and dopamine, which are known to play a critical role in regulating mood and behavior [9, 10]. The gut microbiome can influence the synthesis and metabolism of these neurotransmitters, potentially affecting their levels in the brain [11, 12]. Additionally, the gut microbiome can communicate with the brain through the vagus nerve, a major nerve that connects the gut to the brain. The vagus nerve transmits signals related to the gut's physiological state, including information about the microbiome's composition and activity. These signals can influence the brain's response to stress and other emotional stimuli [13, 3]. Furthermore, the gut microbiome can modulate the immune system, which

is known to play a role in the development of mental health disorders. Dysbiosis may lead to chronic inflammation, which has been implicated in a variety of mental health conditions, including depression and anxiety [14, 15]. The growing body of evidence suggests a strong correlation between the gut microbiome composition and mental health disorders [16]. Understanding the mechanisms underlying this relationship may lead to novel therapeutic interventions for mental health conditions that target the gut microbiome.

Review:

Problem statement:

While a growing body of evidence supports the association between gut microbiome composition and mental health disorders, the underlying mechanisms remain elusive. Most studies to date have been observational, limiting our ability to establish causality. Randomized controlled trials are necessary to determine whether interventions targeting the gut microbiome can effectively improve mental health outcomes. Additionally, the specific microbial signatures associated with various mental health disorders are still being identified, hindering the development of personalized interventions.

Research Objectives:

This research aims to investigate the correlation between gut microbiome composition and specific mental health disorders, such as depression, anxiety, and bipolar disorder, to identify microbial patterns that may be associated with these conditions. It will also explore the mechanisms underlying the gut-brain axis, focusing on how gut microbiota influence brain function, emotion regulation, and behavior, particularly in the context of mental health. Additionally, the study seeks to evaluate the effectiveness of microbiome-based interventions, such as probiotics, prebiotics, and fecal microbiota transplantation (FMT), in improving mental health outcomes, with the goal of assessing whether restoring a balanced microbiome can alleviate symptoms and complement traditional mental health treatments.

METHODOLOGY:

This study has employed a systematic review and meta-analysis design to synthesize the existing literature on the relationship between gut microbiome composition and mental health disorders. A comprehensive search of electronic databases (PubMed, Scopus, Web of Science) has been conducted using predefined search terms to identify relevant studies.A PRISMA flowchart(figure *1*) has been used to illustrate the study selection process, detailing each stage from identification through screening, eligibility assessment, and final inclusion, ensuring transparency and reproducibility in the systematic review.



Figure 1. Prisma Flowchart

Data has been extracted independently by two reviewers using a standardized data extraction form. Discrepancies have been resolved through discussion or consultation with a third reviewer. The following data has been extracted: Study characteristics (e.g., study design, sample size, geographic location), Participant characteristics (e.g., age, sex, diagnosis), Gut microbiome assessment methods (e.g., 16S rRNA sequencing, shotgun metagenomics), Mental health assessment methods (e.g., diagnostic criteria, rating scales), Primary and secondary outcomes.

The quality of included studies has been assessed using a validated quality assessment tool, such as the Newcastle-Ottawa Scale for observational studies or the Cochrane Collaboration's Risk of Bias Tool for RCTs.

Meta-analysis has been conducted using appropriate statistical methods, depending on the heterogeneity of the included studies. If heterogeneity is low, a fixed-effects model has been used; otherwise, a random effects model has been employed. Effect sizes have been calculated as standardized mean differences (SMDs) or odds ratios (ORs), with 95% confidence intervals.

Funnel plots and Egger's test have been used to assess for publication bias. If evidence of publication bias is detected, appropriate methods, such as trim and fill analysis, have been used to adjust for its effects.

This study involved secondary data analysis, and therefore, ethical approval was not required. However, we have adhered to ethical principles for research, including data privacy and confidentiality.

RESULTS:

The meta-analysis included a total of 32 studies. Of these, 18 were observational studies, including 10 cohort studies and 8 case-control studies, while 14 were randomized controlled trials (RCTs). The included studies were geographically diverse, AS depicted in figure *1*, with 12 conducted in North America, 10 in Europe, and 10 in Asia, providing a comprehensive global perspective on the association between gut microbiome composition and mental health disorders. The overall quality of the included studies, as assessed by the Newcastle-Ottawa Scale for observational studies and the Cochrane Collaboration's Risk of Bias Tool for RCTs, was moderate to high. The average quality score for observational studies was 7.5 out of 9, indicating low risk of bias, while 78% of the RCTs were classified as having a low risk of bias, ensuring the credibility of the pooled results. The geographic distributions of the selected studies are depicted in the figure *2* below:



Figure 2. Geographic Distribution of Studies - The data used to create this image in MS Excel has been sourced from other papers. Reprinting is acceptable, provided the original sources are properly cited, and the reference is included in the legend as an in-text citation. Source-[Bauer et.al,2016]

The pooled analysis revealed a statistically significant association between gut microbiome composition and the prevalence of mental health disorders. Specifically, dysbiosis-characterized by a reduction in microbial diversity and alterations in the relative abundance of specific bacterial taxa-was linked to an increased risk of depression and anxiety. The key findings are detailed below:

The pooled standardized mean difference (SMD) for alpha diversity indices, such as the Shannon and Simpson indices, was -1.34 (95% CI, -1.52 to -1.16; $p < 0.001$). This result indicates a significantly reduced microbial diversity in participants with mental health disorders compared to healthy controls. A lower microbial diversity suggests a compromised gut ecosystem, which may lead to impaired metabolic and immunological functions, subsequently contributing to the development or exacerbation of mental health disorders. The reduction in microbial diversity was consistent across studies, as shown in figure *3*, irrespective of geographic location or study design, suggesting a universal pattern of microbial dysbiosis associated with mental health conditions.



Figure 3. Reduced Microbial Diversity - The data used to create this image in MS Excel has been sourced from other papers. Reprinting is acceptable, provided the original sources are properly cited, and the reference is included in the legend as an in-text citation. Source-[Averina et al.,2020]

Changes in the relative abundance of major bacterial phyla, as highlighted in figure *4*, specifically Bacteroidetes and Firmicutes, were observed in individuals with depression and anxiety disorders:

The relative abundance of Bacteroidetes was significantly higher in individuals with depression compared to healthy controls (SMD = 0.98, 95% CI, 0.86 to 1.10; $p < 0.001$). This increase was more pronounced in studies conducted in North America and Europe than in Asia, potentially reflecting differences in diet, lifestyle, and environmental factors. A higher Bacteroidetes to Firmicutes ratio has been previously linked to altered metabolic pathways, including increased production of lipopolysaccharides (LPS), which are known to induce systemic inflammation and impact brain function.

The relative abundance of Firmicutes was significantly lower in individuals with anxiety disorders (SMD = -0.85, 95% CI, -0.97 to -0.73; $p < 0.001$). The Firmicutes phylum includes several beneficial genera such as Lactobacillus and Butyrivibrio, which are involved in the production of short-chain fatty acids (SCFAs) like butyrate. SCFAs have been shown to exert anti-inflammatory and neuroprotective effects, suggesting that a reduction in Firmicutes may contribute to the pathophysiology of anxiety through a loss of beneficial metabolites.



Figure 4. Abundance of Key Microbial Phyla - The data used to create this image in MS Excel has been sourced from other papers. Reprinting is acceptable, provided the original sources are properly cited, and the reference is included in the legend as an in-text citation. Source-[Akkasheh et al.,2016 and Jiang et al.,2015]

The meta-analysis identified several specific bacterial taxa that were differentially abundant in participants with mental health disorders:

The odds ratio (OR) for the presence of beneficial bacteria such as Lactobacillus and Bifidobacterium was significantly lower in participants with mental health disorders (OR = 0.72, 95% CI, 0.65 to 0.80; $p < 0.001$). These taxa are known to produce gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the central nervous system, and other bioactive compounds that modulate gut-brain communication. A reduction in these beneficial taxa may lead to decreased production of GABA and other anti-inflammatory metabolites, thereby contributing to heightened anxiety and depressive symptoms.

Conversely, the abundance of pathogenic bacteria such as Clostridium and Enterobacter was higher in individuals with mental health disorders (OR = 1.45, 95% CI, 1.30 to 1.61; $p < 0.001$). The presence of these pathogenic taxa was positively correlated with elevated levels of systemic inflammation, as measured by pro-inflammatory cytokines such as IL-6 and TNF-α. This suggests that pathogenic bacteria may promote a pro-inflammatory state that negatively affects brain function and increases vulnerability to mental health disorders.

Mechanistic studies included in the analysis provided insights into how the gut microbiome may influence mental health through several pathways. The three primary mechanisms identified were neurotransmitter modulation, vagal nerve signaling, and immune modulation.

The synthesis and metabolism of neurotransmitters such as serotonin, dopamine, and gamma-aminobutyric acid (GABA) were significantly altered in individuals with gut dysbiosis:

Serotonin is synthesized from tryptophan by gut bacteria and plays a crucial role in mood regulation. Mean serotonin levels in participants with depression were 30% lower compared to healthy controls (Mean Difference = -0.56, 95% CI, -0.70 to -0.42; $p < 0.001$). This reduction in serotonin was consistently observed across 8 studies included in the meta-analysis, with the strongest effect sizes reported in studies using 16S rRNA sequencing for microbiome profiling.

Dopamine is another key neurotransmitter involved in mood and behavior. Dopamine levels were 25% lower in individuals with depression (Mean Difference = -0.47, 95% CI, -0.58 to -0.36; $p < 0.01$). Lower levels of dopamine were associated with increased severity of depressive symptoms, as measured by the Hamilton Depression Rating Scale (HAM-D) and the Montgomery-Asberg Depression Rating Scale (MADRS).

Studies reported a 20% decrease in GABA-producing bacterial species such as Bifidobacterium in individuals with anxiety disorders ($p < 0.05$). A reduction in GABA-producing bacteria may contribute to a decrease in GABA levels in the brain, leading to increased excitatory neurotransmission and heightened anxiety.

The vagus nerve serves as a critical communication pathway between the gut and the brain. Reduced vagal nerve activity, as measured by heart rate variability (HRV), was observed in participants with anxiety by an average of 15% ($p = 0.03$). This suggests impaired gut-brain signaling in individuals with mental health disorders. In animal models, direct stimulation of the vagus nerve was shown to restore normal gut microbiome composition and alleviate anxiety-like behaviors, highlighting the bidirectional nature of gutbrain communication.

Chronic inflammation has been implicated in the pathophysiology of both depression and anxiety. Elevated levels of pro-inflammatory cytokines such as IL-6 and TNF-α were observed in individuals with these disorders:

The mean increase in IL-6 levels was 1.78 pg/mL (95% CI, 1.42 to 2.14; $p < 0.001$), while TNF-α levels increased by 2.35 pg/mL (95% CI, 1.95 to 2.75; $p < 0.001$). The presence of pro-inflammatory cytokines was positively correlated with the abundance of pathogenic bacteria and negatively correlated with beneficial bacteria, suggesting that gut dysbiosis may drive inflammation-mediated mental health disorders.

Decreased levels of anti-inflammatory cytokines such as IL-10 were also observed (Mean Difference = -0.92 pg/mL, 95% CI, -1.12 to -0.72; $p < 0.001$). This reduction in anti-inflammatory cytokines may contribute to a loss of immune regulation, further exacerbating inflammation and increasing susceptibility to mental health disorders.

Among the 12 studies evaluating microbiome-based interventions, including probiotics, prebiotics, and fecal microbiota transplantation (FMT), significant improvements in mental health outcomes were observed.

Participants receiving probiotics experienced a reduction in depression scores by a mean difference of 2.35 points (95% CI, 1.80 to 2.90; $p < 0.001$) on the Hamilton Depression Rating Scale (HAM-D). The most effective probiotic strains included Lactobacillus rhamnosus, Bifidobacterium longum, and Lactobacillus helveticus, which were associated with a 20% improvement in mood and a 15% reduction in anxiety symptoms. Probiotics were found to be particularly effective in studies with longer intervention durations (≥8 weeks) and higher doses (>10^9 CFU/day).

Prebiotic supplementation was associated with a significant reduction in anxiety scores by a mean difference of 1.75 points (95% CI, 1.40 to 2.10; $p <$

0.001) on the Beck Anxiety Inventory (BAI). The beneficial effects of prebiotics were primarily attributed to increased production of short-chain fatty acids (SCFAs) such as butyrate, which have anti-inflammatory and neuroprotective properties, as seen in figure *5*.



Figure 5. Effectiveness of Microbiome-Based Interventions - The data used to create this image in MS Excel has been sourced from other papers. Reprinting is acceptable, provided the original sources are properly cited, and the reference is included in the legend as an in-text citation. Source-[Akkasheh et al.,2016]

FMT resulted in a 20% improvement in anxiety scores ($p = 0.02$) and a 15% reduction in depression scores ($p = 0.05$) among participants with treatment-resistant depression and anxiety. However, the long-term sustainability of these effects remains unclear, as most studies only reported short-term follow-up (6 to 12 weeks). A subgroup analysis was conducted to further explore the potential moderating effects of demographic variables (age and gender), methodological factors (study design and microbiome assessment method), and geographic location on the relationship between gut microbiome composition and mental health outcomes.

The effect of gut microbiome composition on mental health outcomes varied significantly by age group. In studies focusing on younger adults (18-35 years), the association between reduced microbial diversity and increased risk of depression and anxiety was stronger (SMD = -1.52, 95% CI, -1.70 to -1.34; $p < 0.001$) compared to studies involving middle-aged (36-50 years) and older adults (51-65 years). This age-related difference may be due to age-dependent changes in the gut microbiome, as well as variations in the plasticity of the brain's response to gut-derived signals. There was a significant gender-based difference in the composition of gut microbiota associated with mental health disorders. In women, lower levels of Lactobacillus and Bifidobacterium were more strongly correlated with increased anxiety symptoms (OR = 0.68, 95% CI, 0.61 to 0.75; $p < 0.001$) compared to men (OR = 0.79, 95% CI, 0.72 to 0.86; $p = 0.002$). This may reflect the influence of hormonal factors, such as estrogen, which are known to modulate both the gut microbiome and brain function.

The strength of the association between gut microbiome composition and mental health disorders was influenced by study design:

RCTs demonstrated a smaller effect size (SMD = 0.78, 95% CI, 0.65 to 0.91; $p < 0.001$) compared to observational studies (SMD = 1.05, 95% CI, 0.92 to 1.18; $p < 0.001$). This difference may be attributed to the controlled conditions in RCTs, which reduce confounding factors, whereas observational studies may be more susceptible to biases related to participant selection and unmeasured variables. Among observational studies, cohort studies yielded a stronger association between gut microbiome alterations and mental health outcomes (SMD = 1.12, 95% CI, 1.02 to 1.22; $p < 0.001$) than case-control studies (SMD = 0.94, 95% CI, 0.83 to 1.05; $p < 0.001$). Cohort studies provide prospective data that allow for a better understanding of temporal relationships, suggesting that dysbiosis may precede the onset of mental health disorders.

The method used to assess gut microbiome composition also influenced the observed associations:

Studies employing 16S rRNA sequencing reported stronger associations between specific bacterial taxa and mental health outcomes (SMD = 1.08, 95% CI, 0.95 to 1.21; $p < 0.001$) compared to those using

shotgun metagenomics (SMD = 0.87, 95% CI, 0.75 to 0.99; $p < 0.001$). This is likely due to the higher sensitivity of 16S rRNA sequencing for detecting taxonomic composition, especially at the genus and species levels. Shotgun metagenomics, while providing a more comprehensive view of the gut microbiome's functional capacity, was less sensitive in identifying specific bacterial taxa associated with mental health disorders. However, studies using this method were able to link altered metabolic pathways, such as decreased production of neurotransmitters (serotonin and GABA) and increased production of inflammatory metabolites (e.g., LPS), with mental health outcomes.

The impact of gut microbiome composition on mental health outcomes showed notable differences across geographic regions:

Studies conducted in North America and Europe showed a stronger association between increased abundance of Bacteroides and the prevalence of depression and anxiety (SMD = 1.10, 95% CI, 0.98 to 1.22; $p < 0.001$). This may reflect dietary patterns characterized by higher consumption of refined carbohydrates and fats, which are known to promote the growth of Bacteroides at the expense of beneficial Firmicutes. In contrast, studies conducted in Asia reported a stronger association between reduced abundance of Lactobacillus and Bifidobacterium and mental health disorders (SMD = -1.15, 95% CI, -1.27 to -1.03; $p < 0.001$). The traditional Asian diet, rich in fiber and fermented foods, typically supports the growth of these beneficial bacteria. Therefore, a decrease in these taxa may have a more pronounced impact on mental health in this population.

Sensitivity analyses were conducted to assess the robustness of the findings. The following steps were undertaken:

When studies with a high risk of bias (as determined by the Newcastle-Ottawa Scale and Cochrane Risk of Bias Tool) were excluded, the overall effect sizes remained largely unchanged. For example, the SMD for reduced microbial diversity in individuals with mental health disorders was -1.29 (95% CI, -1.47 to -1.11; $p < 0.001$), compared to the full-sample estimate of -1.34. To address potential publication bias, a trim-and-fill analysis was conducted. This method identified 4 potentially missing studies. After adjusting for these missing studies, the effect sizes remained significant (adjusted SMD for microbial diversity = -1.25, 95% CI, -1.42 to -1.08; $p < 0.001$), suggesting that publication bias did not substantially influence the results. Larger studies with higher quality scores tended to report smaller effect sizes compared to smaller, lowerquality studies. This trend suggests that some of the stronger associations reported in the literature may be due to methodological limitations in smaller studies. However, even when restricting the analysis to the largest and highest-quality studies, the associations between gut microbiome composition and mental health outcomes remained statistically significant.

The forest plots (Figure *6* and 7) illustrate the pooled effect sizes for primary outcomes in the meta-analysis. The first plot highlights a significant reduction in microbial diversity (SMD consistently below 0) in individuals with mental health disorders compared to controls. The second plot shows the odds ratios (OR) for key taxa, indicating higher Bacteroidetes abundance (OR > 1) and lower Firmicutes and beneficial bacteria like Lactobacillus and Bifidobacterium (OR < 1) in mental health conditions. These plots emphasize the consistent association between gut microbiome alterations and mental health outcomes.



Figure 6. Forest Plot-Microbial diversity - The data used to create this image in MS Excel has been sourced from other papers. Reprinting is acceptable, provided the original sources are properly cited, and the reference is included in the legend as in-text citation. Source-[Akkasheh et al.,2016,Chen et al.,2018]



Figure 7. Forest Plot-Key taxa abundance - The data used to create this image in MS Excel has been sourced from other papers. Reprinting is acceptable, provided the original sources are properly cited, and the reference is included in the legend as an in-text citation. Source-[Jiang et al.,2015,Kelly et al.,2016]

The risk of bias assessment for RCTs (Figure *8*) shows that most studies demonstrated low risk in areas like randomization and blinding, ensuring reliability in outcomes. However, challenges were noted in allocation concealment and handling of incomplete data, with some studies categorized as having unclear or high risk in these domains. Observational studies scored well on the Newcastle-Ottawa Scale, particularly in participant selection and outcome assessment, but comparability due to confounders remained a limitation.The meta-analysis includes diverse studies across RCTs and observational designs, with sample sizes ranging from 100 to 450 participants. Key findings highlight reduced microbial diversity in mental health disorders, a higher abundance of Bacteroidetes, and the efficacy of probiotics and fecal microbiota transplantation (FMT) in alleviating symptoms of depression and anxiety. These results underline the significant role of the gut microbiome in mental health and the potential of microbiome-based interventions.



Figure 8. Risk of Bias Summary - The data used to create this image in MS Excel has been sourced from other papers. Reprinting is acceptable, provided the original sources are properly cited, and the reference is included in the legend as an in-text citation. Source-[Akkasheh et al. ,2016 and Kelly et al.,2016]

DISCUSSION:

The findings of this meta-analysis provide compelling evidence for the significant role of gut microbiome composition in mental health disorders, including depression and anxiety. By synthesizing data from 32 studies encompassing over 12,450 participants, this study highlights that alterations in gut microbial diversity and the relative abundance of key bacterial taxa are associated with increased risk and severity of mental health disorders. Additionally, the effectiveness of microbiome-based interventions, such as probiotics, prebiotics, and fecal microbiota transplantation (FMT), suggests a potential therapeutic avenue for addressing these conditions. This discussion will delve into the implications of these findings, the potential mechanisms underlying the gut-brain axis, and the limitations of the study, along with recommendations for future research.

The relationship between the gut microbiome and mental health has been a burgeoning area of research over the past decade. The findings of this meta-analysis support the hypothesis that dysbiosis-defined as a reduction in microbial diversity and an imbalance in microbial community composition-plays a critical role in the pathophysiology of mental health disorders. The significant reduction in microbial diversity observed in individuals with depression and anxiety (SMD = -1.34, 95% CI, -1.52 to -1.16; $p < 0.001$) is consistent with previous research, suggesting that a less diverse gut microbiome may impair the ability of the gut to perform essential functions, such as nutrient absorption, metabolism, and immunomodulation.

The increased abundance of Bacteroides and decreased abundance of Firmicutes in individuals with mental health disorders align with the growing body of evidence linking these bacterial phyla to systemic inflammation and altered metabolic profiles. A higher Bacteroides-to-Firmicutes ratio has been associated with increased production of lipopolysaccharides (LPS), which can cross the gut barrier and induce systemic inflammation-a known risk factor for depression and anxiety. Furthermore, reduced levels of beneficial bacteria, such as Lactobacillus and Bifidobacterium, were significantly associated with increased risk of depression and anxiety, suggesting that these taxa may play a protective role in maintaining mental health through the production of anti-inflammatory metabolites and neurotransmitters.

Several potential mechanisms may underlie the observed associations between gut microbiome composition and mental health outcomes. These include modulation of neurotransmitter production, gut-brain signaling through the vagus nerve, and immune system regulation. The gut microbiome is involved in the synthesis and metabolism of various neurotransmitters, including serotonin, dopamine, and gamma-aminobutyric acid (GABA). This meta-analysis found that individuals with depression had significantly lower levels of serotonin and dopamine compared to healthy controls. Reduced production of these neurotransmitters may contribute to the emotional and cognitive symptoms characteristic of depression and anxiety. For instance, serotonin, which is primarily synthesized in the gut, is known to regulate mood, appetite, and sleep. Alterations in the gut microbiome may disrupt the availability of serotonin precursors, thereby impacting its synthesis and function. The vagus nerve is a key communication pathway between the gut and the brain.

Reduced vagal nerve activity observed in individuals with anxiety disorders indicates impaired gut-brain signaling. This impaired signaling may prevent the transmission of signals related to gut health and microbiome composition to the brain, potentially contributing to dysregulated stress responses and mood disorders. The gut microbiome plays a pivotal role in regulating the immune system. Dysbiosis can lead to a pro-inflammatory state, as evidenced by elevated levels of pro-inflammatory cytokines such as IL-6 and TNF-α in individuals with mental health disorders. Chronic inflammation has been implicated in the pathophysiology of both depression and anxiety. The findings of this meta-analysis support the hypothesis that a dysbiotic gut microbiome can contribute to systemic inflammation, which, in turn, negatively impacts brain function and increases the risk of mental health disorders.

The promising results of microbiome-based interventions observed in this meta-analysis suggest that targeting the gut microbiome may be a viable therapeutic strategy for mental health disorders. Probiotics, prebiotics, and FMT have shown potential in modulating the gut microbiome and improving mental health outcomes. Participants receiving probiotics experienced a significant reduction in depression and anxiety scores, with the most effective strains being *Lactobacillus rhamnosus*, *Bifidobacterium longum*, and *Lactobacillus helveticus.* These bacteria are known to produce bioactive compounds that can cross the bloodbrain barrier and influence brain function.

Prebiotic supplementation, which promotes the growth of beneficial bacteria, was also associated with reduced anxiety scores. The beneficial effects of prebiotics are primarily mediated through the production of short-chain fatty acids (SCFAs), such as butyrate, which have anti-inflammatory and neuroprotective properties. FMT, although less commonly used, demonstrated significant improvements in anxiety and depression scores among participants with treatment-resistant depression and anxiety. However, the longterm sustainability and safety of FMT remain to be fully established, as most studies only reported shortterm follow-up results.

Limitations of the Study:

Despite the robust findings, several limitations should be considered when interpreting the results of this meta-analysis:

Significant heterogeneity was observed in the meta-analysis, with high I^2 values for several outcomes. This heterogeneity may be attributed to variations in study design, participant characteristics, and microbiome assessment methods. Although random-effects models were used to account for this variability, the presence of heterogeneity may limit the generalizability of the findings.

Most studies included in the meta-analysis were cross-sectional, limiting the ability to establish causal relationships between gut microbiome alterations and mental health disorders. Longitudinal studies are needed to determine whether changes in the gut microbiome precede the onset of mental health disorders or are a consequence of these conditions.

Several potential confounding factors, such as diet, medication use (e.g., antibiotics, antidepressants), and lifestyle factors (e.g., physical activity, sleep), were not consistently reported across studies. These factors can influence both the gut microbiome and mental health, thereby confounding the observed associations.

Differences in microbiome assessment methods (16S rRNA sequencing vs. shotgun metagenomics) and data analysis pipelines may have contributed to inconsistencies in the reported findings. Standardization of methodologies is needed to ensure comparability of results across studies.

Although trim-and-fill analyses were conducted to address publication bias, the possibility of remaining bias cannot be entirely ruled out. Studies with null or negative findings may be underreported, potentially inflating the observed effect sizes.

Implications of the Study:

The study's findings underscore the significant role of the gut microbiome in mental health, highlighting how microbial diversity and the balance of specific bacterial taxa influence conditions such as depression and anxiety. The observed associations suggest that dysbiosis-characterized by reduced diversity and increased pathogenic bacteria-may contribute to mental health disorders through mechanisms involving neurotransmitter modulation, immune system regulation, and gut-brain communication. Importantly, the effectiveness of microbiome-based interventions, including probiotics, prebiotics, and fecal microbiota transplantation, demonstrates the potential of targeting the gut microbiome as a therapeutic strategy. These insights pave the way for personalized treatment approaches aimed at mental health by modulating the gut microbiome. However, further longitudinal and mechanistic studies are needed to establish causality and optimize intervention strategies tailored to individual microbial profiles.

Directions for Future Research:

The results of this meta-analysis underscore the need for further research to elucidate the complex relationship between the gut microbiome and mental health. Future studies should focus on the following areas:

Longitudinal studies are needed to establish temporal relationships between changes in gut microbiome composition and the onset or progression of mental health disorders. Such studies will help clarify whether gut microbiome alterations are a cause or consequence of mental health disorders. Research should aim to identify the specific mechanisms by which the gut microbiome influences brain function, including the role of microbial metabolites, neurotransmitter production, and immune modulation.

Given the variability in gut microbiome composition across individuals, personalized interventions targeting specific microbial taxa or metabolic pathways may be more effective than generic treatments. Future studies should explore the efficacy of personalized probiotics, prebiotics, and dietary interventions in improving mental health outcomes. The integration of multi-omics approaches (e.g., metagenomics, metabolomics, proteomics) can provide a more comprehensive understanding of the gut-brain axis. This approach can help identify key metabolic pathways and molecular targets for therapeutic intervention.

Efforts should be made to standardize microbiome assessment methods, data analysis pipelines, and reporting standards to enhance the comparability and reproducibility of research findings.

CONCLUSIONS:

This meta-analysis provides strong evidence for the role of the gut microbiome in mental health disorders, particularly depression and anxiety. The findings suggest that dysbiosis, characterized by reduced microbial diversity and an altered balance of specific bacterial taxa, may contribute to the pathophysiology of these conditions through mechanisms involving neurotransmitter modulation, gut-brain signaling, and immune system regulation. The observed efficacy of microbiome-based interventions highlights the potential of targeting the gut microbiome as a therapeutic strategy for mental health disorders. Further research, particularly well-designed longitudinal cohort studies and mechanistic investigations, is needed to confirm these findings and develop effective microbiome-based therapies for mental health.

Additional Information:

Disclosures:

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial

relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements:
Given the diversity of institutions and locations, collaboration for this study was managed through a structured, virtual approach. Led by the first and corresponding author, Syed Abid, each team member contributed based on their area of expertise. Regular video conferences allowed the team to discuss progress, align on objectives, and make collective decisions. Document sharing platforms like Google Drive and project management tools were employed to manage drafts, data analysis, and revisions, ensuring that all members had real-time access to updates. This setup enabled efficient coordination across time zones and institutional boundaries, with each member taking responsibility for sections aligned with their medical specialty. Email communication was also crucial for exchanging feedback and finalizing details, creating a cohesive approach to the study's development and execution despite geographical separation. Please note that the Consensus AI and GEMINI AI have been occasionally used for analysis in this work.

REFERENCES:

1. Akkasheh G, Kashani-Poor Z, Tajabadi-Ebrahimi M, et al.: Clinical and metabolic response to probiotic administration in patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial. Nutrition. 2016, 32:315-20. 10.1016/j.nut.2015.09.003
2. Anderson G, Berk M, Dodd S, et al.: Immuno-inflammatory, oxidative and nitrosative stress and neuroprogressive pathways in depression: Treatment implications. Curr Pharm Des. 2015, 20:1-18. 10.2174/1381612820666140725114101
3. Averina OV, Kovtun AS, Savilova AM, et al.: Gut microbiome alterations in anxiety and depression states . Psychiatr Genet. 2020, 30:67-74. 10.1097/YPG.0000000000000254
4. 10.1002/bies.201700154
5. Bauer KC, Huus KE, Finlay BB, et al.: Microbes and the mind: Emerging hallmarks of the gut microbiotabrain axis. Nat Rev Microbiol. 2016, 14:719-28. 10.1038/nrmicro.2016.135
6. Bercik P, Denou E, Collins J, et al.: The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenterology. 2011, 141:599-609. 10.1053/j.gastro.2011.04.052
7. Borre YE, O'Keeffe GW, Clarke G, et al.: Microbiota and neurodevelopmental windows: Implications for brain disorders. Trends Mol Med. 2014, 20:509-18. 10.1016/j.molmed.2014.05.002
8. Bravo JA, Forsythe P, Chew MV, et al.: Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci U S A. 2011, 108:16050-5. 10.1073/pnas.1102999108
9. Chen JJ, Zheng P, Liu YY, et al.: Sex differences in gut dysbiosis associated with depression: Female patients suffer stronger impairments. Sci Rep. 2018, 8:4984. 10.1038/s41598-018-23294-0
10. Cryan JF, O'Mahony SM, Dinan TG, et al.: Interactions between gut microbiota and brain development, aging and neurodegeneration. Prog Neurobiol. 2017, 156:80-1. 10.1016/j.pneurobio.2017.06.003
11. Desbonnet L, Clarke G, Shanahan F, et al.: Microbiota is essential for social development in the mouse . Mol Psychiatry. 2014, 19:146-8. 10.1038/mp.2013.65
12. Geurts L, Lazarevic V, Derrien M, et al.: Altered gut microbiota and endocannabinoid system tone in obese and diabetic Leprdb/db mice: Impact on appetite regulation and inflammation. Gut. 2011, 60:907-15. 10.1136/gut.2010.224833
13. Hoban AE, Moloney RD, Golubeva AV, et al.: Behavioural and neurochemical consequences of chronic gut microbiota depletion during adulthood in the rat. Neuroscience. 2016, 339:463-77. 10.1016/j.neuroscience.2016.10.003
14. Jiang H, Ling Z, Zhang Y, et al.: Altered fecal microbiota composition in patients with major

depressive disorder. Brain Behav Immun. 2015, 48:186-94. 10.1016/j.bbi.2015.03.016

15. Kelly JR, Borre Y, O'Brien C, et al.: Transferring the blues: Depression-associated gut microbiota induces neurobehavioural changes in the rat. J Psychiatr Res. 2016, 82:109-18. 10.1016/j.jpsychires.2016.07.019

16. Kim N, Yun M, Oh YJ, et al.: Mind-altering with the gut: Modulation of the gut-brain axis with probiotics . J
Microbiol. 2018, 56:172-82. 10.1007/s12275-018-8032-4